BioCentury | Apr 14, 2021
Management Tracks

CEO succession at Amarin; plus Lilly, IGM, Jounce and more

...Therapeutics Inc. (NASDAQ:ONCT) hired Chase Leavitt as general counsel. Leavitt was general counsel at Lineage Cell Therapeutics Inc....
BioCentury | Mar 27, 2021
Regulation

March 26 Quick Takes: ADCs from Astellas-Seagen, Gilead under EMA review; plus Pfizer-Lilly, BrainStorm and Ilya

...for whom analgesics are ineffective or not appropriate. BrainStorm’s NurOwn meets in Phase II MS studyBrainStorm Cell Therapeutics Inc....
BioCentury | Mar 3, 2021
Product Development

FDA seeks to dampen expectations on BrainStorm ALS therapy amid patient push for access

...something more substantial,” FDA said of the BrainStorm Cell Therapeutics Inc....
...Steve Usdin contributed to this report BC Staff BrainStorm Cell Therapeutics Inc. Neurology Amyotrophic...
BioCentury | Jan 30, 2021
Product Development

ALS looks up as clinical pipeline explodes

...growth factor support is NurOwn from BrainStorm Cell Therapeutics Inc....
...Koch Biogen Inc. Ionis Pharmaceuticals Inc. Novartis AG Prilenia Therapeutics B.V. BrainStorm Cell Therapeutics Inc. Alexion...
BioCentury | Jan 23, 2021
Management Tracks

Yale’s Fuchs joins Genentech, Roche; plus Lineage’s Roberts jumps on Longboard as CFO and Avidity, Xalud, AVM, Novavax

...is director of the Yale Cancer Center and physician-in-chief of Smilow Cancer Hospital.Brandi Roberts left Lineage Cell Therapeutics Inc....
BioCentury | Dec 2, 2020
Emerging Company Profile

Sofinnova’s Papiernik, Costa and Roche alum Garibaldi carve orphan neurology play Noema out of the pharma’s assets

...which was acquired by CTI BioPharma Corp. (NASDAQ:CTIC...
BioCentury | Nov 18, 2020
Product Development

Nov. 17 Quick Takes: Phase III miss for BrainStorm’s ALS program; plus Novo, BioMarin-Deep Genomics, Lexicon, Seed-Lilly and RhoVac

...By BioCentury Staff BrainStorm sees path forward for ALS therapy despite Phase III missBrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI...
...JITC).TARGETSGLP-1 – Glucagon-like peptide-1PSA (KLK3) - Prostate-specific antigenRHOC - Ras homolog family member C BC Staff BrainStorm Cell Therapeutics Inc. Lexicon...
BioCentury | Sep 3, 2020
Management Tracks

Dier joining Ultragenyx as CFO; plus Magenta, Galectin, Immunicum, BrainStorm, Vaccinex

...core duties as the immuno-oncology company’s CSO. Rohmann was acting CEO of Oasmia Pharmaceutical AB (SSE:OASM).BrainStorm Cell Therapeutics Inc....
BioCentury | May 29, 2020
Management Tracks

Delaney takes over as Assembly’s CSO; plus NGM, TCR2, Amunix, Evox, Vor and more

...Investment Authority, the sovereign wealth fund for the State of Qatar. Neurodegenerative diseases company BrainStorm Cell Therapeutics Inc....
...Inc. (NYSE-A:PFNX). Robin Sawka, Staff Writer Assembly Biosciences Inc. NGM Biopharmaceuticals Inc. TCR2 Therapeutics Inc. Evox Therapeutics Ltd. Vor Biopharma Inc. BrainStorm Cell Therapeutics Inc. Sierra...
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

..."ORIC Raises $55M to Fund Trials in Drug Resistant Cancers" ). Neurodegenerative diseases company BrainStorm Cell Therapeutics Inc....
...development at Orion Corp. (HSE:ORNAV; HSE:ORNBV). Robin Sawka, BioCentury Staff Redpin Therapeutics Inc. Relmada Therapeutics Inc. Assembly Biosciences Inc. BrainStorm Cell Therapeutics Inc. Promethera...
Items per page:
1 - 10 of 831
BioCentury | Apr 14, 2021
Management Tracks

CEO succession at Amarin; plus Lilly, IGM, Jounce and more

...Therapeutics Inc. (NASDAQ:ONCT) hired Chase Leavitt as general counsel. Leavitt was general counsel at Lineage Cell Therapeutics Inc....
BioCentury | Mar 27, 2021
Regulation

March 26 Quick Takes: ADCs from Astellas-Seagen, Gilead under EMA review; plus Pfizer-Lilly, BrainStorm and Ilya

...for whom analgesics are ineffective or not appropriate. BrainStorm’s NurOwn meets in Phase II MS studyBrainStorm Cell Therapeutics Inc....
BioCentury | Mar 3, 2021
Product Development

FDA seeks to dampen expectations on BrainStorm ALS therapy amid patient push for access

...something more substantial,” FDA said of the BrainStorm Cell Therapeutics Inc....
...Steve Usdin contributed to this report BC Staff BrainStorm Cell Therapeutics Inc. Neurology Amyotrophic...
BioCentury | Jan 30, 2021
Product Development

ALS looks up as clinical pipeline explodes

...growth factor support is NurOwn from BrainStorm Cell Therapeutics Inc....
...Koch Biogen Inc. Ionis Pharmaceuticals Inc. Novartis AG Prilenia Therapeutics B.V. BrainStorm Cell Therapeutics Inc. Alexion...
BioCentury | Jan 23, 2021
Management Tracks

Yale’s Fuchs joins Genentech, Roche; plus Lineage’s Roberts jumps on Longboard as CFO and Avidity, Xalud, AVM, Novavax

...is director of the Yale Cancer Center and physician-in-chief of Smilow Cancer Hospital.Brandi Roberts left Lineage Cell Therapeutics Inc....
BioCentury | Dec 2, 2020
Emerging Company Profile

Sofinnova’s Papiernik, Costa and Roche alum Garibaldi carve orphan neurology play Noema out of the pharma’s assets

...which was acquired by CTI BioPharma Corp. (NASDAQ:CTIC...
BioCentury | Nov 18, 2020
Product Development

Nov. 17 Quick Takes: Phase III miss for BrainStorm’s ALS program; plus Novo, BioMarin-Deep Genomics, Lexicon, Seed-Lilly and RhoVac

...By BioCentury Staff BrainStorm sees path forward for ALS therapy despite Phase III missBrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI...
...JITC).TARGETSGLP-1 – Glucagon-like peptide-1PSA (KLK3) - Prostate-specific antigenRHOC - Ras homolog family member C BC Staff BrainStorm Cell Therapeutics Inc. Lexicon...
BioCentury | Sep 3, 2020
Management Tracks

Dier joining Ultragenyx as CFO; plus Magenta, Galectin, Immunicum, BrainStorm, Vaccinex

...core duties as the immuno-oncology company’s CSO. Rohmann was acting CEO of Oasmia Pharmaceutical AB (SSE:OASM).BrainStorm Cell Therapeutics Inc....
BioCentury | May 29, 2020
Management Tracks

Delaney takes over as Assembly’s CSO; plus NGM, TCR2, Amunix, Evox, Vor and more

...Investment Authority, the sovereign wealth fund for the State of Qatar. Neurodegenerative diseases company BrainStorm Cell Therapeutics Inc....
...Inc. (NYSE-A:PFNX). Robin Sawka, Staff Writer Assembly Biosciences Inc. NGM Biopharmaceuticals Inc. TCR2 Therapeutics Inc. Evox Therapeutics Ltd. Vor Biopharma Inc. BrainStorm Cell Therapeutics Inc. Sierra...
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

..."ORIC Raises $55M to Fund Trials in Drug Resistant Cancers" ). Neurodegenerative diseases company BrainStorm Cell Therapeutics Inc....
...development at Orion Corp. (HSE:ORNAV; HSE:ORNBV). Robin Sawka, BioCentury Staff Redpin Therapeutics Inc. Relmada Therapeutics Inc. Assembly Biosciences Inc. BrainStorm Cell Therapeutics Inc. Promethera...
Items per page:
1 - 10 of 831